Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: van Rossum, Ineke A.a; * | Visser, Pieter Jellea; e | Knol, Dirk L.b | van der Flier, Wiesje M.a; b | Teunissen, Charlotte E.c | Barkhof, Frederikd | Blankenstein, Marinus A.c | Scheltens, Philipe
Affiliations: [a] Department of Neurology/Alzheimer Center, VU Medical Center, Amsterdam, The Netherlands | [b] Department of Epidemiology and Biostatistics, VU Medical Center, Amsterdam, The Netherlands | [c] Department of Clinical Chemistry, VU Medical Center, Amsterdam, The Netherlands | [d] Department of Radiology, VU Medical Center, Amsterdam, The Netherlands | [e] Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Center Limburg, VU Medical Center, Amsterdam, The Netherlands
Correspondence: [*] Correspondence to: Ineke van Rossum, Alzheimer Center VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. Tel.: +31 204448527; Fax: +31 204440715; E-mail: i.vanrossum@vumc.nl.
Abstract: Alzheimer's disease (AD) is a common cause of mild cognitive impairment (MCI). However, the time between the diagnosis of MCI and the diagnosis of dementia is highly variable. In this study we investigated which known risk factors and biomarkers of AD pathology were associated with rapid progression from MCI to dementia. Of the 203 subjects with MCI, 91 progressed to AD-type dementia and were considered to have MCI-AD at baseline. Subjects with MCI-AD were older, more frequently female and carrier of the APOE-ε4 allele, had lower scores on the Mini-Mental State Examination (MMSE), more medial temporal lobe atrophy (MTA) and lower levels of Aβ1-42 and increased levels of t-tau and p-tau in the cerebrospinal fluid (CSF) compared to subjects without AD-type dementia at follow up. Of the 91 subjects with MCI-AD, we had data available of CSF (n = 56), MTA (n = 76), and APOE-genotype (n = 63). Among the subjects with MCI-AD, MTA (hazard ratio (HR) 2.2, p = 0.004) and low MMSE score (HR 2.0 p = 0.007) were associated with rapid progression to dementia. High CSF t-tau (HR 1.7, p = 0.07) and p-tau (1.7, p = 0.08) tended to be associated with rapid progression to dementia. CSF Aβ1-42, APOE status, age, gender, and educational level were not associated with time to dementia. Our findings implicate a different role for biomarkers in diagnosis and prognosis of MCI-AD. While amyloid markers can be used to identify MCI-AD, injury markers may predict rapid progression to dementia.
Keywords: Alzheimer's disease, biomarkers, cerebrospinal fluid, clinical progression, magnetic resonance imaging, mild cognitive impairment
DOI: 10.3233/JAD-2011-111694
Journal: Journal of Alzheimer's Disease, vol. 29, no. 2, pp. 319-327, 2012
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl